Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogeneous IL-2.
暂无分享,去创建一个
B. Dörken | S. Meuer | M. Körbling | R. Haas | A. Pezzutto | S. Cayeux | R. Schulz
[1] L. Samelson,et al. Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck , 1989, Nature.
[2] N. Tonks,et al. CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Haynes,et al. A novel activation pathway for mature thymocytes. Costimulation of CD2 (T,p50) and CD28 (T,p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation , 1988, The Journal of experimental medicine.
[4] B. Dörken,et al. B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. , 1988, Blood.
[5] Charles A. Janeway,et al. Receptor-directed focusing of lymphokine release by helper T cells , 1988, Nature.
[6] Y. Humblet,et al. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. , 1987, Experimental hematology.
[7] S. Meuer,et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.
[8] C. Nathan,et al. Secretory products of macrophages. , 1987, The Journal of clinical investigation.
[9] M. López-Botet,et al. Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation , 1987, European journal of immunology.
[10] R. Brookmeyer,et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. , 1985, Blood.
[11] R. Mertelsmann,et al. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. , 1984, Blood.
[12] J. Adams,et al. Role of interleukin-2 in depressed T-cell mitogenesis after allogeneic marrow transplantation in man. , 1984, Leukemia research.
[13] J. Biggs,et al. Human bone marrow allograft recipients: production of, and responsiveness to, interleukin 2. , 1983, Journal of immunology.
[14] R. Storb,et al. Impaired autologous and allogeneic mixed lymphocyte reaction in human marrow transplant recipients. , 1983, Experimental hematology.
[15] W. Falk,et al. Activation of cytotoxic T lymphocytes requires at least two spleen cell-derived helper factors besides interleukin 2. , 1983, Journal of immunology.
[16] R. Storb,et al. Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. , 1983, Journal of immunology.
[17] D. Linch,et al. T cell regeneration after allogeneic and autologous bone marrow transplantation , 1982, British journal of haematology.
[18] M. Körbling,et al. 4‐Hydroperoxyclophosphamide: a model for eliminating residual human tumour cells and T‐lymphocytes from the bone marrow graft , 1982, British journal of haematology.
[19] R. Storb,et al. Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. , 1979, Journal of immunology.
[20] H. Ochs,et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. , 1978, Blood.
[21] M. R. Mickey,et al. Immunodeficiency following allogeneic bone marrow transplantation. , 1978, Transplantation proceedings.
[22] S. Ferrone,et al. Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. , 1975, Clinical immunology and immunopathology.